Overview

A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Dose escalation study with a dose expansion phase, to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of two dose levels of BKM120 when administered orally.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals